发明名称 ASRGL1 IN ENDOMETRIAL CANCER
摘要 There is provided a method for determining whether a mammalian subject having an endometrial cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of ASRGL1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.
申请公布号 US2016054324(A1) 申请公布日期 2016.02.25
申请号 US201414782538 申请日期 2014.04.04
申请人 ATLAS ANTIBODIES AB 发明人 Edqvist Per-Henrik;Ponten Fredrik
分类号 G01N33/574;C07K16/40 主分类号 G01N33/574
代理机构 代理人
主权项
地址 Stockholm SE